ProUroCare Medical Inc.
PUMD
Other OTC0.00
USD
- -
- -
ISIN
US74373C2061
CUSIP
74373C206
Return %
Stock
S&P500
1Y
0.00
26.84
3Y
0.00
77.03
5Y
- -
80.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Benjamin Banks
- Full Time Employees
- 2
- Sector
- Technology
- Industry
- Consumer Electronics
- Address
- 6440 Flying Cloud Drive Eden Prairie United States of America
- IPO Date
- Nov 29, 2022
- Website
- prourocare.com
- Similar Companies
- Business
- ProUroCare Medical Inc. is a medical technology company specializing in the development and commercialization of innovative products for the detection and characterization of male urological prostate disease. Its core product is the ProUroScan System, a tactile elasticity imaging device that uses a handheld pressure-sensing rectal probe coupled with advanced image construction software to generate real-time 2D and 3D color maps of the prostate. This system supplements conventional digital rectal examinations (DRE) by providing high-resolution visual documentation of prostate abnormalities, aiding physicians in detecting and monitoring prostate disease. ProUroCare operates primarily in the healthcare equipment sector, targeting urologists and medical centers specializing in prostate health. Founded in 1999 and headquartered in Eden Prairie, Minnesota, ProUroCare collaborates extensively with Artann Laboratories to advance its patented mechanical imaging technology. The company primarily serves the U.S. market with its proprietary medical imaging solutions. In recent developments, ProUroCare received FDA clearance for its ProUroScan Elasticity Imaging System, enabling commercial distribution and clinical adoption in key metropolitan medical centers. The firm has pursued strategic initiatives to expand its intellectual property portfolio and is actively seeking partnerships to enhance sales and service support capabilities within the urologic marketplace. Recent major changes include intensified efforts to commercialize the ProUroScan technology following FDA clearance and ongoing research and development collaborations with technology partners to further innovate prostate imaging modalities. ProUroCare has focused on augmenting its product offerings by integrating advanced imaging features that enhance clinical diagnostics and documentation standards, positioning its system as a potential new standard of care in urology. The company maintains operational and regulatory activities aligned with U.S. healthcare standards, emphasizing its role in improving prostate disease detection and management. ProUroCare Medical Inc. is publicly traded under the ticker PUMD on the OTC Pink market and continues to develop proprietary medical imaging systems that leverage patented technology for the urology field. Aside from its flagship ProUroScan system, the company remains committed to innovation and strategic growth within the urological diagnostic device industry.